People: Veloxis Pharmaceuticals A/S (VELOX.CO)

VELOX.CO on Copenhagen Stock Exchange

1.02DKK
8:14am EDT
Change (% chg)

kr.0.01 (+0.99%)
Prev Close
kr.1.01
Open
kr.1.01
Day's High
kr.1.02
Day's Low
kr.1.00
Volume
339,302
Avg. Vol
--
52-wk High
--
52-wk Low
--

Search Stocks

Summary

Name Age Since Current Position

Mette Agger

51 2015 Chairman of the Board

William Polvino

54 2009 Chief Executive Officer, President

Thomas Dyrberg

61 2009 Independent Deputy Chairman of the Board

Johnny Stilou

47 2008 Chief Financial Officer, Executive Vice President

John Weinberg

47 2014 Chief Operating Officer, Executive Vice President

Christina Sylvest

Senior Vice President Global Clinical Development & Operations

Breian Knudsen

Vice President Technical Operations

Bob Dufour

2014 Head of Sales and Marketing

Steve Bourke

2014 Head of Market Access and Reimbursement

Michelle Mc Guinness

2014 Global Head of Regulatory Affairs and Quality Assurance

Vincenza Nigro

2014 Head of Medical Affairs Activities

Michael Heffernan

50 2015 Director

Anders Goetzsche

47 2008 Independent Director

Biographies

Name Description

Mette Agger

Ms. Mette Kirstine Agger has been Chairman of the Board of Directors of Veloxis Pharmaceuticals A/S since March 26, 2015. She has been Independent Director of the Company since April 21, 2010. She is Member of the Compensation Committee of the Company. She is Executive Director with LFI A/S and Member of the Boards of Directors of Harboes Bryggeri A/S, Statens Serum Institute and Epitherapeutics ApS. She has international pharmaceutical experience.

William Polvino

Dr. William J. Polvino, M.D. has served as Chief Executive Officer and President at Veloxis Pharmaceuticals A/S since September 2009. Dr. Polvino leads the activities for Veloxis in the US and is responsible for the clinical and regulatory group, including medical affairs, as well as business development activities. Dr. Polvino brings experience in the senior management of pharmaceutical companies together with experience in clinical as well as product development. Earlier in his career, Dr. Polvino was CEO at Helsinn Therapeutics (US), Inc. In his capacity as the President and CEO of Sapphire Therapeutics, Inc. Dr. Polvino began his career as an MD from UMDNJ-Robert Wood Johnson Medical School, US. He joined the life sciences industry in 1991, upon following training in Internal Medicine at Massachusetts General Hospital and a fellowship in Clinical Pharmacology at the National Institutes of Health, US. Dr. Polvino had various positions of increasing responsibility within clinical research, drug development, and executive functions at Merck, Wyeth Pharmaceuticals (now Pfizer Inc), and Theravance, Inc, until he joined Sapphire Therapeutics in 2002.

Thomas Dyrberg

Dr. Thomas Dyrberg, M.D. has served as Independent Deputy Chairman of the Board of Directors of Veloxis Pharmaceuticals A/S since 2009. He has been Member of the Board of Directors of the Company since September 2003. He is Member of the Compensation Committee of the Company. He is also Senior Partner with Novo A/S and Member of the Boards of Directors of Lux Biosciences Inc, Ophthotech Corp and Allocure Inc. He has international pharmaceutical experience. He holds a Doctorate of Medicine from Koebenhavns Universitet.

Johnny Stilou

Mr. Johnny Stilou has served as Chief Financial Officer, Executive Vice President at Veloxis Pharmaceuticals A/S since 2008. He is responsible for the activities within Finance, IT, Legal Affairs, and Investor Relations. Prior to joining Veloxis, Mr. Stilou held a number of CFO positions with international technology and Medicare companies. Mr. Stilou began his career with KPMG in Denmark in 1986. From 1995, he held various senior finance positions within the GN Great Nordic group until 2003. Mr. Stilou holds a Master of Science in Economics and Business Administration from the Copenhagen Business School.

John Weinberg

Dr. John D. Weinberg, M.D. has served as Executive Vice President and Chief Operating Officer at Veloxis Pharmaceuticals A/S since March 6, 2014. Before that, he has been Executive Vice President, Chief Commercial Officer at the Company since July 2010. He is responsible for managing all Commercial activities supporting the Veloxis portfolio of compounds in development. Additionally, Dr. Weinberg directs Corporate Strategy and Pipeline Target Identification. Prior to joining Veloxis, Dr. Weinberg was Business Franchise Head at Novartis Pharmaceuticals Corporation in the transplant and infectious disease business unit. Earlier in his career, Dr. Weinberg served as Oncology Business Unit Head at Enzon Pharmaceuticals, Inc, from 2003 to 2005. From 1996 to 2003, Dr. Weinberg held various positions within the Global Marketing function at Wyeth Pharmaceuticals. Dr. Weinberg received his MD degree from the University of the Witwatersrand School of Medicine, Johannesburg, South Africa, and his Master of Business Administration degree from INSEAD in Fontainebleau, France.

Christina Sylvest

Ms. Christina Sylvest serves as Senior Vice President Global Clinical Development & Operations at Veloxis Pharmaceuticals A/S. She joined the Company in April 2008. She is responsible for clinical development, clinical operations and drug supply. Ms. Sylvest has experience in conducting clinical studies both within the pharmaceutical industry and the CRO business. Prior to joining Veloxis, Mrs. Sylvest held the position as director of clinical operations at Rheoscience A/S, where she established the clinical operations department and led the execution and management of the company's clinical studies. She was a member of the management team and involved in establishing the company strategy. Prior positions for Ms. Sylvest include global project management responsibility at Quintiles A/S and establishment of the NovoSeven clinical operations surgery group at Novo Nordisk A/S. Ms. Sylvest holds an MSc in pharmacy from the Pharmaceutical University of Copenhagen.

Breian Knudsen

Mr. Breian Knudsen serves as Vice President Technical Operations at Veloxis Pharmaceuticals A/S. Prior to joining Veloxis, Mr. Knudsen held a position as Principal Scientist, Chemistry Manufacturing & Controls (CMC) project manager at Novo Nordisk A/S where he headed the CMC part of a number of solid dosage development projects and where he implemented guidelines for systematic in-house and external transfer of manufacturing processes. Mr. Knudsen holds an MSc in pharmacy from the Pharmaceutical University of Copenhagen.

Bob Dufour

Mr. Bob Dufour has been appointed Head of Sales and Marketing of Veloxis Pharmaceuticals A/S as of June 3, 2014. He has worked in both sales and marketing roles at Abbott, Wyeth and Auxillium. Mr. Dufour has prior transplant commercial experience having managed the marketing activities for Wyeth’s Rapamune transplant franchise.

Steve Bourke

Mr. Steve Bourke has been appointed Head of Market Access and Reimbursement of Veloxis Pharmaceuticals A/S as of June 3, 2014. He has joined from Ipsen Pharmaceuticals, where he was responsible for market access and patient services. Prior to that, he worked for Celgene. Steve trained as a pharmacist and has worked as both a retail pharmacist and within a specialty pharmacy organization that provided patient access to specialized products.

Michelle Mc Guinness

Ms. Michelle Mc Guinness has been appointed Global Head of Regulatory Affairs and Quality Assurance of Veloxis Pharmaceuticals A/S as of June 3, 2014. She joins Veloxis with over 15 years of senior regulatory and quality affairs experience from Mylan, Octagon Research Solutions (now part of Accenture), Sanofi-Aventis, and Ranbaxy.

Vincenza Nigro

Ms. Vincenza Nigro has been appointed Head of Medical Affairs Activities of Veloxis Pharmaceuticals A/S as of June 3, 2014. She has transplant experience from her prior work at Roche where she supported the mycophenolate franchise. In her role with Veloxis, Vincenza is responsible for publication strategy and for support of dissemination of scientific information to transplant physicians and surgeons and for the conduct of Phase IV clinical studies.

Michael Heffernan

Anders Goetzsche

Mr. Anders Goetzsche been Independent Member of the Board of Directors of Veloxis Pharmaceuticals A/S since April 2008. He is Chairman of the Audit Committee of the Company. He is Executive Vice President and Chief Financial Officer of H. Lundbeck A/S. He has competencies in Finance. He holds a Master of Science degree in Accounting from Syddansk Universitet from 1991.
Search Stocks